...• ORR and DR according to RECIST 1.1 as determined by investigatorreview, and OS• invPFS, ORR, DR, and OS in patients with baseline T790M mutationsconfirmed by central EGFR mutation assay•Change from baseline in QOL as measured using the PRO of EORTCQLQ-C30, EORTC QLQ-LC13, the DLQI, and the EQ-5D followingtreatment with CO-1686 versus erlotinib• Treatment-emergent AEs, laboratory abnormalities and ECGabnormalities• Plasma PK parameters for CO-1686 based on sparse sampling`- ORR and DR according to RECIST 1.1 as determined by investigator review, and OS- invPFS, ORR, DR, and OS in patients with baseline T790M mutations confirmed by central EGFR mutation assay- Change from baseline in QOL as measured using the PRO of EORTC QLQ-C30, EORTC QLQ-LC13, the DLQI, and the EQ-5D following treatment with CO-1686 versus erlotinib- Treatment-emergent AEs, laboratory abnormalities and ECG abnormalities- Plasma PK parameters for CO-1686 based on sparse sampling - TRO y DR según RECIST (versión 1.1) conforme lo determine el investigador mediante su evaluación y la ST- SSPinv, TRO, DR y ST en pacientes con mutaciones T790M en el momento inicial, confirmadas por ensayo central de mutación en el EGFR- Cambio desde el momento inicial en la CDV, valorado mediante los cuestionarios RSP de EORTC QLQ-C30, EORTC QLQ-LC13, el DLQI y el EQ-5D tras el tratamiento con CO-1686 en comparación con erlotinib- AAs durante el tratamiento, anomalías analíticas y electrocardiográficas (ECG)- Parámetros FC en plasma para CO-1686 a partir de muestreos puntuales`• ORR and DR according to RECIST 1.1 as determined by investigator review, and OS• invPFS, ORR, DR, and OS in patients with baseline T790M mutations confirmed by central EGFR mutation assay•Change from baseline in QOL as measured using the PRO of EORTC QLQ-C30, EORTC QLQ-LC13, the DLQI, and the EQ-5D following treatment with CO-1686 versus erlotinib• Treatment-emergent AEs, laboratory abnormalities and ECG abnormalities• Plasma PK parameters for CO-1686 based on sparse sampling • TRO et DR, et TCM selon les critères RECIST version 1.1, déterminés par l’évaluation de l’investigateur, et SG• SSPinv, TRO, DR, et SG chez des patients porteurs de mutations T790M, à la visite de référence, confirmées par un test de recherche des mutations EGFR réalisé centralement• Variations par rapport à la visite de référence de la QdV mesurée à l’aide des RRP du questionnaire EORTC QLQ C30, EORTC QLQ LC13, de l’index DLQI, et du questionnaire EQ-5D après traitement par le CO-1686 par rapport à l’ertolinib• Événements indésirables (EI) apparus pendant le traitement, anomalies biologiques et anomalies à l’électrocardiogramme (ECG) • Paramètres PK plasmatiques du CO-1686 sur des échantillons épars`• ORR and DR according to RECIST 1.1 as determined by investigator review, and OS• invPFS, ORR, DR, and OS in patients with baseline T790M mutations confirmed by central EGFR mutation assay• Change from baseline in QOL as measured using the PRO of EORTC QLQ-C30, EORTC QLQ-LC13, the DLQI, and the EQ-5D following treatment with CO-1686 versus erlotinib• Treatment-emergent AEs, laboratory abnormalities and ECG abnormalities• Plasma PK parameters for CO-1686 based on sparse sampling • ORR e DR secondo i criteri RECIST Versione 1.1, determinati dall’analisi dello sperimentatore, e OS• PFSsper, ORR, DR e OS nei pazienti con mutazioni T790M al basale confermate dal test delle mutazioni dell’EGFR eseguito a livello centrale• Variazione rispetto al basale della QOL, misurata utilizzando i PRO di EORTC QLQ C30, EORTC QLQ LC13, l’indice DLQI e il questionario EQ-5D in seguito al trattamento con CO-1686 rispetto a erlotinib• (EA emergenti dal trattamento, anomalie di laboratorio e anomalie nell’elettrocardiogramma (ECG) • Parametri PK plasmatici per CO-1686 basati su campionamento ridotto...